Odyssey Therapeutics, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
As of June 30, 2026, Odyssey Therapeutics held $433.1M in cash and equivalents, expected to fund operations into H2 2028. Q2 2026 net loss was $52.8M (vs. $41.2M in Q2 2025); R&D expenses increased to $36.2M from $30.2M YoY. The company plans to initiate Phase 2b monotherapy and Phase 2a combination trials (with vedolizumab) for OD-001 in H2 2026, with topline data expected H2 2027, and file a CTA for OD-002 by end of 2026.
Why this rating
Adequate cash runway and on-track clinical progress are positive, but increased burn rate ($38.4M adjusted loss Q2) and typical biotech development risk keep this routine for clinical-stage firm.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.